Abstract
Immune checkpoint inhibitors are today an essential therapy for the management of primary lung cancer. These monoclonal antibodies nevertheless expose patients to immune-related adverse events. Do patients with preexisting autoimmune disease derive the same benefit from immunotherapy as others? Are they more at risk of toxicity? What is the risk of flare of their underlying autoimmune disease? The aim of this article is to synthesize the data available in the literature on the use of immune checkpoint inhibitors in patients with both lung cancer and autoimmune disease.© 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
